nach oben

Erschienen in:

09.06.2017 | Hepatitiden | FORTBILDUNG . ÜBERSICHT

Stoffwechsel, Knochen, Herz-Kreislauf — was bei AIDS-Patienten anders ist

Gesundheitsvorsorge bei HIV-Infizierten

verfasst von: Prof. Dr. med. Hans-Jürgen Stellbrink

Erschienen in: MMW - Fortschritte der Medizin | Sonderheft 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

In der Therapie HIV-Infizierter müssen neben den Folgen der Immunsuppression Risiken wie Rauchen, Drogenkonsum und sexuell übertragbare Erkrankungen beachtet werden. Hinzu kommen Nebenwirkungen der antiretroviralen Medikation und zunehmend typische altersassoziierte Risiken. Dieser Beitrag fokussiert auf Maßnahmen, die zusätzlich zur Therapie und zum Monitoring der HIV-Infektion erforderlich sind.

Jallow A, Ljunggren G, Wandell P, Carlsson AC. Prevalence, incidence, mortality and co-morbidities amongst human immunodeficiency virus (HIV) patients in Stockholm County, Sweden — the Greater Stockholm HIV Cohort Study. AIDS Care. 2015;27:142–9CrossRefPubMed

Rasmussen LD, May MT, Kronborg G, Larsen CS, Pedersen C, Gerstoft J et al. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. Lancet HIV. 2015;2:e288–98CrossRefPubMed

Schouten J, Wit FW, Stolte IG, Kootstra NA, van d, V, Geerlings SE et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787–97CrossRefPubMed

Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6CrossRefPubMed

Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378–84CrossRefPubMed

Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373:795–807CrossRefPubMed

Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian R et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003;17:2015–23CrossRefPubMed

Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS. 2009;20:595–600CrossRefPubMed

Heuft MM, Houba SM, van den Berk GE, Smissaert vdH, van Dam AP, Dijksman LM et al. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS. 2014;24;28(7):999–1005CrossRefPubMed

10.

Cheng A, Chang SY, Sun HY, Tsai MS, Liu WC, Su YC et al. Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy. J Infect Dis. 2017;215:606–13PubMed

11.

Cianflone NF, Wallace MR. Stimulating Evidence for Pneumococcal Conjugate Vaccination Among HIV-Infected Adults. J Infect Dis. 2015;212:1–4CrossRef

12.

Zaaqoq AM, Khasawneh FA, Smalligan RD. Cardiovascular Complications of HIV-Associated Immune Dysfunction. Cardiol Res Pract. 2015;2015:302638.

13.

Erlandson KM, O’Riordan M, Labbato D, McComsey GA. Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;65:290–8CrossRefPubMedPubMedCentral

14.

Gazzola L, Bellistri GM, Tincati C, Ierardi V, Savoldi A, Del SA et al. Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. J Transl Med. 2013;11:51CrossRefPubMedPubMedCentral

15.

Jansen K, Thamm M, Bock CT, Scheufele R, Kucherer C, Muenstermann D et al. High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany. PLoS ONE 2015;10(11):e0142515CrossRefPubMedPubMedCentral

16.

Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Curr Opin HIV AIDS 2016;11(5):521–6CrossRefPubMed

17.

18.

Brejt N, Gilleece Y, Fisher M. Acute hepatitis C: changing epidemiology and association with HIV infection. J HIV Ther. 2007;12:3–6PubMed

19.

Ghosn J, Pierre-Francois S, Thibault V, Duvivier C, Tubiana R, Simon A et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med. 2004;5:303–6CrossRefPubMed

20.

van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010;24:1799–812CrossRefPubMed

21.

Vogel M, Deterding K, Wiegand J, Gruner NH, Baumgarten A, Jung MC et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis. 2009;49:317–9CrossRefPubMed

22.

El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016;64:130–7CrossRefPubMed

23.

Franceschi S, Jaffe H. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis. 2007;45:510–3CrossRefPubMed

24.

Yinnon AM, Coury-Doniger P, Polito R, Reichman RC. Serologic response to treatment of syphilis in patients with HIV infection. Arch Intern Med. 1996;156:321–5CrossRefPubMed

25.

Kotsafti O, Paparizos V, Kourkounti S, Chatziioannou A, Nicolaidou E, Kapsimali V et al. Early syphilis affects markers of HIV infection. Int J STD AIDS. 2016;27:739–45CrossRefPubMed

26.

Palacios R, Jimenez-Onate F, Aguilar M, Galindo MJ, Rivas P, Ocampo A et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44:356–9CrossRefPubMed

27.

Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med 2015;162:335–44CrossRefPubMed

28.

Elliot ER, Singh S, Tyebally S, Gedela K, Nelson M. Recreational drug use and chemsex among HIV-infected in-patients: a unique screening opportunity. HIV Med. 2017; doi: 10.1111/hiv.12487. [Epub ahead of print]

29.

Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R. Prevalence of and factors associated with depression among people living with HIV in France. HIV Med. 2016; doi: 10.1111/hiv.12438. [Epub ahead of print]

30.

Carrieri MP, Marcellin F, Fressard L, Preau M, Sagaon-Teyssier L, Suzan-Monti M et al. Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey). PLoS ONE. 2017;12(2):e0171645CrossRefPubMedPubMedCentral

31.

Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161:1–10CrossRefPubMedPubMedCentral

32.

Gomes A, Reyes EV, Garduno LS, Rojas R, Mir MG, Del RE et al. Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy. PLoS ONE. 2016;11:e0160797CrossRefPubMedPubMedCentral

33.

Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. [Updated 2015 Jun 12]. In: De Groot LJ, Chrousos G, Dungan K et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326741

34.

Gomes AR, Souteiro P, Silva CG, Sousa-Pinto B, Almeida F, Sarmento A et al. Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy. BMC Infect Dis. 2016;16:628CrossRefPubMedPubMedCentral

35.

Martin-Iguacel R, Negredo E, Peck R, Friis-Moller N. Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV. Curr Hypertens Rep. 2016;18:46CrossRefPubMed

36.

van Zoest RA et al. Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure. Clin Infect Dis. 2016;63:205–13CrossRefPubMed

37.

Gravemann S, Brinkkoetter PT, Vehreschild JJ, Franke B, Ehren K, Bunemann E et al. Low-grade proteinuria is highly prevalent in HIV-positive patients on antiretroviral treatment. AIDS. 2014;28:1783–9CrossRefPubMed

38.

Ibrahim F, Naftalin C, Cheserem E, Roe J, Campbell LJ, Bansi L et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS. 2010;24:2239–44CrossRefPubMed

39.

Roe J, Campbell LJ, Ibrahim F, Hendry BM, Post FA. HIV care and the incidence of acute renal failure. Clin Infect Dis. 2008;47:242–9CrossRefPubMed

40.

Franceschini N, Napravnik S, Finn WF, Sczech LA, Eron JJ, Jr. Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;42:368–72CrossRefPubMed

41.

Franceschini N, Napravnik S, Eron JJ, Jr., Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 2005;67:1526–31CrossRefPubMed

42.

Alvarez E, Belloso WH, Boyd MA, Inkaya AC, Hsieh E, Kambugu A et al. Which HIV patients should be screened for osteoporosis: an international perspective. Curr Opin HIV AIDS. 2016;11:268–76CrossRefPubMed

43.

D’Abramo A, Zingaropoli MA, Oliva A, D’Agostino C, Al MS, De LG et al. Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients. PLoS ONE. 2016;11:e0149601CrossRefPubMedPubMedCentral

44.

Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–12CrossRefPubMedPubMedCentral

45.

Bhagwat P, Ofotokun I, McComsey GA, Brown T, Moser C, Sugar CA et al. Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation. Conference on Retroviruses and Opportunistic Infections, February 13–16, 2017, Seattle, Washington, Abstract No. 695

46.

Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. Transl Res. 2017;183:41–56CrossRefPubMed

47.

Macias J, Pineda JA, Real LM. Non-Alcoholic Fatty Liver Disease in HIV Infection. AIDS Rev. 2017;19:35–46PubMed

48.

Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM et al. Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy. Clin Infect Dis. 2015;60:1569–78PubMedPubMedCentral

49.

Rivero-Juarez A, Camacho A, Merchante N, Perez-Camacho I, Macias J, Ortiz-Garcia C et al. Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS ONE. 2013;8:e68953CrossRefPubMedPubMedCentral

50.

Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol. 2013;47:182–7CrossRefPubMedPubMedCentral

51.

Guaraldi G, Lonardo A, Ballestri S, Zona S, Stentarelli C, Orlando G et al. Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. Arch Med Res. 2011;42:690–7CrossRefPubMed

52.

Ofotokun I, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F et al. Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS. 2016;30:405–14CrossRefPubMedPubMedCentral

53.

Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T et al. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis. 2015;212:1241–9CrossRefPubMedPubMedCentral

54.

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18:905–13CrossRefPubMed

55.

Haverkort ME, van der Spek BW, Lips P, Slieker WA, ter HR, Huitema AD et al. Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. Scand J Infect Dis. 2011;43:821–6CrossRefPubMed

56.

Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200:1746–54CrossRefPubMed

57.

Borges AH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V et al. Antiretrovirals, fractures and osteonecrosis in a large international HIV cohort. Clin Infect Dis. 2017;64:1413–21CrossRefPubMed

58.

Wyatt CM. Antiretroviral therapy and the kidney. Top Antivir Med 2014;22:655–8PubMed

59.

Moriyama Y, Minamidate Y, Yasuda M, Ehara H, Kikuchi M, Tsuchiya T et al. Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient. Urol Res. 2008;36:275–7CrossRefPubMed

60.

Nishijima T, Hamada Y, Watanabe K, Komatsu H, Kinai E, Tsukada K et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS ONE. 2013;8:e77268CrossRefPubMedPubMedCentral

61.

Tattevin P, Revest M, Chapplain JM, Ratajczak-Enselme M, Arvieux C, Michelet C. Increased risk of renal stones in patients treated with atazanavir. Clin Infect Dis. 2013;56:1186CrossRefPubMed

62.

Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012;55:1262–9CrossRefPubMed

63.

Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25:1671–3CrossRefPubMed

64.

Iwata K, Nagata M, Watanabe S, Nishi S. Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report. BMC Pharmacol Toxicol. 2016;17:52CrossRefPubMedPubMedCentral

65.

Bhogal S. Tenofovir-Induced Fanconi Syndrome Presenting as Hypokalemic Periodic Paralysis. Am J Ther. 2016 [Epub ahead of print]

66.

Lify B, Dabo G, Nascimento O, Iraqui S, Elkhayat S, Zamd M et al. Fanconi syndrome induced by tenofovir: A case report. Saudi J Kidney Dis Transpl. 2016;27:808–11CrossRefPubMed

67.

Mitra S, Priscilla R, Rajeev K, Sauradeep S, Rajkumar S, Cherian AO. Renal tubular dysfunction associated with tenofovir therapy. J Assoc Physicians India. 2014;62:580–2PubMed

68.

Gupta SK, Anderson AM, Ebrahimi R, Fralich T, Graham H, Scharen-Guivel V et al. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS ONE. 2014;9:e92717CrossRefPubMedPubMedCentral

69.

Gutierrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014;16:199–212PubMed

70.

Maggi P, Montinaro V, Rusconi S, Di BA, Bellagamba R, Bonfanti P et al. The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. HIV Clin Trials. 2014;15:87–91CrossRefPubMed

71.

Brothers CH, Hernandez JE, Cutrell AG, Curtis L, it-Khaled M, Bowlin SJ et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20–8CrossRefPubMed

72.

Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep. 2010;7:127–33CrossRefPubMed

73.

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318–30CrossRefPubMed

74.

Lewis JM, Stott KE, Monnery D, Seden K, Beeching NJ, Chaponda M et al. Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort. Int J STD AIDS. 2016;27:105–9CrossRefPubMed

75.

Tseng A, Foisy M. Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. Curr Infect Dis Rep. 2012;14:67–82CrossRefPubMed

Titel: Stoffwechsel, Knochen, Herz-Kreislauf — was bei AIDS-Patienten anders ist
Gesundheitsvorsorge bei HIV-Infizierten
verfasst von: Prof. Dr. med. Hans-Jürgen Stellbrink
Publikationsdatum: 09.06.2017
Verlag: Springer Medizin
Schlagwörter: Hepatitiden
HIV
Pflege
Hepatitis B
Tenofovir
Impfungen
Erschienen in: MMW - Fortschritte der Medizin / Ausgabe Sonderheft 2/2017
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI: https://doi.org/10.1007/s15006-017-9047-1

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Gesundheitsvorsorge bei HIV-Infizierten

Zusammenfassung

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Allgemeinmedizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2017

Die PrEP schützt — wenn sie sachgerecht eingesetzt wird

PrEP: Profitieren Frauen weniger?

Erneut Heilungsversuch gescheitert

Kutane Warnlampe für den HIV-Test

Erfolgreiches HIV-Management

HIV-Therapie mit Proteaseinhibitor

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Allgemeinmedizin